ImmunoGen’s IMGN632 for Rare Blood Cancer Secures Breakthrough Therapy Designation

The FDA has granted ImmunoGen’s IMGN632 a Breakthrough Therapy designation for treating patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare form of blood cancer.

IMGN632 is a biopharmaceutical that targets a specific antigen in cancers affecting the blood, bone marrow and lymph nodes. Unlike chemotherapy, the drug can target and kill tumor cells while sparing healthy cells.

ImmunoGen is also seeking an approval for IMGN632 for the treatment of acute myeloid leukemia, among other indications.